RxDoctor Payments Data

Aditya Mehra, MD

Cardiovascular Disease · Brick, NJNPI 1922274141

Payments from drug & device makers

$42,694in general payments, 2019–2025

Across 650 payments — averaging $65.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$17K
  • Medtronic$12K
  • Abbott$4K
  • Abiomed$3K
  • Boston Scientific$800
  • AstraZeneca$619
  • plus $4K from 40 others
$29in research payments, 2019–2025

Across 1 payment — averaging $29.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$29

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$15,98038%
  • Travel & lodging$11,98128%
  • Food & beverage$13,72533%
  • Education$1330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,694 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,585,195
Medicare patients
2,505
Services billed
12,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban236$315,897
XareltoRivaroxaban241$302,668
EntrestoSacubitril/Valsartan66$88,250
BrilintaTicagrelor42$39,808
Repatha SureclickEvolocumab22$20,317
FarxigaDapagliflozin Propanediol24$19,151
JardianceEmpagliflozin11$10,818
Praluent PenAlirocumab11$10,083
Metoprolol Succinate612$9,073
Losartan Potassium403$5,224
Atorvastatin Calcium478$4,991
Diltiazem 24hr Er (Cd)Diltiazem Hcl100$3,582
Rosuvastatin Calcium266$3,486
Amlodipine Besylate395$3,444
ClopidogrelClopidogrel Bisulfate217$3,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$578$315,897236 claims
Johnson & JohnsonXarelto$17,459$302,668241 claims
NovartisEntresto$357$88,25066 claims
AstraZenecaBrilinta, Farxiga$619$58,95966 claims
Boehringer IngelheimJardiance$97$10,81811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →